Research programme: monoclonal antibody biosimilars - TOT BiopharmAlternative Names: BCIA07; TAA013; TAB 014; TAD 011; TAT014; TOT104
Latest Information Update: 09 Jan 2017
At a glance
- Originator TOT Biopharm
- Developer Lees Pharmaceutical Holdings; TOT Biopharm
- Class Monoclonal antibodies
- Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Mantle-cell lymphoma; Solid tumours; Wet age-related macular degeneration